HomeDiabetesOtelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint – News

Comments

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint – News — No Comments

Leave a Reply

Your email address will not be published. Required fields are marked *